Home
Site Map
         
  Blood Sugar Levels
  Types of Insulin
  Diabetic Supplies
  Insulin Storage & Use
  Insulin & Diabetes
Inhaled Insulin
   
  About Diabetes
  Diabetic Diet
Regulating Insulin
   
  Resources for Diabetics
   
 
 
 

Inhaled Insulin: A Medical Breakthrough for Diabetes Control

As of January 2006, diabetics can effectively avoid shots when taking insulin. Early this year, the FDA approved Exubera®, an inhaled insulin powder, for treatment of type 1 and type 2 diabetes. This approval came on the coattails of European regulators approval early this year.

Sponsored Links
What Is Diabetes?
Get expert help for allergies in children and adults - free resources at MSN Health.
health.msn.com

Diabetes from Zyprexa or Seroquel
Have you used the Anti-psychotics Zyprexa or Seroquel? If you have diabetes and have taken Zyprexa and Seroquel, then you may qualify for a legal claim for compensation.
www.class-action-lawsuits.com

Diabetes Realted Eye Disorders
Diabetes and eye problems need to be examined by an eye doctor. Call day or night to make an appointment. Experienced surgeons on staff with many possible treatments.
www.lunaeye.com


Approval of Exubera, the brand name of inhaled insulin developed by collaborators Pfizer, Sanofi-Aventis and Nektar Therapeutics, has been right around the corner for more than four years.

After years of delays, during which additional clinical evaluations of Exubera were performed, the product received a boost. On September 8, 2005 the Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 7 to 2 in favor of approval.

Because Exubera is a first-of-its-kind product and designed for long-term use, on October 28, 2005 the FDA announced that it would need an additional three months to study Pfizer's application.

Now, with the recent approval in place, Exubera will be a viable option for diabetics before the end of the year.

About Inhaled Insulin
The inhaler delivers a cloud of powdered insulin to the lungs where it is absorbed into the bloodstream. Unfortunately, only about ten percent of the drug is actually absorbed and the amount delivered and available for absorption would vary depending on the technique used and the health of the patient. In addition, the current data from Pfizer indicate that the product is only as effective at controlling blood sugar levels as injected insulin, not more so.

Pfizer has recommended against approving the drug for use by smokers. During clinical trials Pfizer discovered that participants who smoked absorbed significantly more of the drug that those who did not smoke.

The results of early testing of Exubera indicated a drop in lung function for some participants. Pfizer continued to study this result and reported that the drop was not significant. The EMDAC agreed that the product is safe for use by people without lung disease. However, they voted 5 to 4 that the drug's safety for those with lung diseases such as asthma, chronic bronchitis and emphysema, had not been verified.

So far, Exubera is approved for management of type 1 and type 2 diabetes in adults only. Pfizer has not sought approval for use in children.

The Inhaled Insulin Market
Exubera and other inhaled insulin products are designed to replace the short-acting insulin injections used following meals. Some diabetics will still require long-acting insulin injections at night or in the morning.

Most diabetics would likely cut down their insulin injections to once daily if they had an option. A number of pharmaceutical companies are banking on this response.

While Exubera is the first inhaled insulin product to be submitted to the FDA for approval, other manufacturers have an inhaled insulin product in the works. Eli Lilly & Co./Alkermes Inc., Novo Nordisk and MannKind Corp. are each working on inhaled insulin, but are still several years behind Pfizer.

AIR®Insulin, the inhaled insulin product produced by collaborators Eli Lily & Company and Alkermes Inc. is currently in Phase 3 long-term safety trials.

MannKind, a biopharmaceutical company, is also currently in Phase 3 clinical trials in both the US and Europe for its inhaled insulin product (Technosphere® Insulin System) and proprietary delivery device (MedTone® inhaler).

Unlike the other powdered inhaled insulin products, Novo Nordisk has partnered with Aradigm to create a liquid inhaled insulin. The AERx® Insulin Diabetes Management system is also in Phase 3 clinical trials.

FDA approval of Exubera will pave the way for these and other novel insulin products and will have a profound effect on the future of diabetes management.

Resources

Alkermes, Inc. (nd). AIR® Insulin (human insulin inhalation powder; also known as HIIP). Product pipeline.

Aradigm Corp. (2005, June 14). Aradigm announces Novo Nordisk presentation of data of AERx Insulin Diabetes Management System at the American Diabetes Association Annual Meeting. Press Release.

Endocrinologic and Metabolic Drugs Advisory Committee Meeting. (2005, September 8). Final minutes [NDA 21-8698 Exubera®].

Pfizer Inc. (2005, October 28). Pfizer and Sanofi-Aventis statement on status of Exubera. Investor News Release.

Pollack, A. (2005, September 9). FDA panel endorses inhaled form of insulin. The New York Times.

Sanofi-Aventis. (2005, October 14). Exubera® receives positive opinion from CHMP for the treatment of type 1 and type 2 diabetes . Press Release.
   
   
 
 
 
 
 
  We proudly subscribe to the principles set
forth by the Health on the Net Foundation.
View our certificate
 
Last modified 18 September 2006
Questions or comments? Please contact our Webmaster.
About Us, Terms of Use, Privacy Policy, Medical Board
© NCERx LLC 2006. All rights reserved.